Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Alpha Cognition Inc (TSE:ACOG)
CNQX:ACOG
RESEARCH TOOLSreports
Holding TSE:ACOG?
Track your performance easily
ACOG Stock Chart & Stats
Day’s RangeC$0 - C$0
52-Week RangeC$7.02 - C$24.73
Previous CloseC$8.05
Volume3.50K
Average Volume (3M)2.91K
Market Cap
C$125.03M
Enterprise ValueC$124.77M
Total Cash (Recent Filing)$1.40M
Total Debt (Recent Filing)$1.22M
Price to Earnings (P/E)―
Beta-0.51
Next Earnings
Apr 24, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.02
Shares Outstanding6,034,221
10 Day Avg. Volume3,738
30 Day Avg. Volume2,911
Standard Deviation0.27
R-Squared0.20
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)-10.26
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-9.16
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Alpha Cognition Inc News
PremiumCompany Announcements
Alpha Cognition Plans Nasdaq Listing and $25M Offering
PremiumCompany Announcements
Alpha Cognition Inc. Appoints New Finance VP
PremiumCompany Announcements
Alpha Cognition Secures U.S. Patent for Alzheimer’s Drug
PremiumCompany Announcements
Alpha Cognition Announces Executive Shake-up & Drug Approval
PremiumCompany Announcements
Alpha Cognition Inc. Secures $4.545M in Bridge Financing
PremiumCompany Announcements
Alpha Cognition Secures Patent for Alzheimer’s Drug ZUNVEYLPremiumCompany Announcements
Alpha Cognition Inc. Adjusts Funding Strategy Amid Market ChallengesOptions Prices
Currently, No data available
---
Ownership Overview
ACOG FAQ
What was Alpha Cognition Inc’s price range in the past 12 months?
Alpha Cognition Inc lowest stock price was C$7.02 and its highest was C$24.73 in the past 12 months.
What is Alpha Cognition Inc’s market cap?
Currently, no data Available
When is Alpha Cognition Inc’s upcoming earnings report date?
Alpha Cognition Inc’s upcoming earnings report date is Apr 24, 2025 which is in 153 days.
How were Alpha Cognition Inc’s earnings last quarter?
Alpha Cognition Inc released its earnings results on Nov 15, 2024. The company reported -C$0.436 earnings per share for the quarter, beating the consensus estimate of -C$1.362 by C$0.926.
Is Alpha Cognition Inc overvalued?
According to Wall Street analysts Alpha Cognition Inc’s price is currently Overvalued.
Does Alpha Cognition Inc pay dividends?
Alpha Cognition Inc does not currently pay dividends.
What is Alpha Cognition Inc’s EPS estimate?
Alpha Cognition Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Alpha Cognition Inc have?
Alpha Cognition Inc has 15,531,282 shares outstanding.
What happened to Alpha Cognition Inc’s price movement after its last earnings report?
Alpha Cognition Inc reported an EPS of -C$0.436 in its last earnings report, beating expectations of -C$1.362. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Alpha Cognition Inc?
Currently, no hedge funds are holding shares in TSE:ACOG
---
Alpha Cognition Inc Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Insider Transactions
Bought Shares
Worth C$126.9K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-16.36%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
195.65%
Trailing 12-Months
Company Description
Alpha Cognition Inc
Alpha Cognition Inc is a clinical-stage biopharmaceutical company dedicated to developing treatments for under-served neurodegenerative diseases such as Alzheimer's Disease and Amyotrophic Lateral Sclerosis. ALPHA-1062 is a patented new chemical entity that has demonstrated safety and improved tolerability in human clinical trials. It is being developed as a new acetylcholine esterase inhibitor for the treatment of dementia of the Alzheimer's type, with minimal gastrointestinal side effects and novel routes of administration.
---
Technical Analysis
---